163 related articles for article (PubMed ID: 9593165)
1. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
Spangler SK; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Mar; 40(3):772-5. PubMed ID: 8851609
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Deshpande LM; Diekema DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):81-8. PubMed ID: 10529885
[TBL] [Abstract][Full Text] [Related]
8. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
Clark CL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2295-8. PubMed ID: 10471582
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
13. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
Giamarellou H; Voutsinas D; Xirouchaki E
J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
[TBL] [Abstract][Full Text] [Related]
16. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
18. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.
Ribera A; Jurado A; Ruiz J; Marco F; Del Valle O; Mensa J; Chaves J; Hernández G; Jiménez de Anta MT; Vila J
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):123-8. PubMed ID: 11858908
[TBL] [Abstract][Full Text] [Related]
20. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
